(AOF) – Biosenic announces that it has raised 500,000 euros in gross proceeds through a private placement of 12 million new shares at an issue price of 0.041 euros per share from institutional investors, Gestys and Friedland Gestion. This company specializing in serious autoimmune and inflammatory diseases and cell therapy intends to use the net proceeds of the offering to prepare an application for FDA authorization for the Phase 3 study in chronic graft disease against the host (cGvHD). They will also cover general business costs.
Payment and delivery of the new shares is expected to take place on or around February 6, 2024. The total dilution to existing shareholders resulting from the issuance of the new shares amounts to 6.95%.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
